Myomo, Inc. (MYO): ANSOFF-Matrixanalyse

In der sich schnell entwickelnden Landschaft der Medizintechnik steht Myomo, Inc. (MYO) an der Spitze der Innovation in der neurologischen Rehabilitation und positioniert sich strategisch, um die Fähigkeiten von Hilfsmitteln durch einen umfassenden Wachstumsansatz zu transformieren. Durch die Nutzung der Ansoff-Matrix stellt das Unternehmen eine mutige Roadmap vor, die Marktdurchdringung, internationale Expansion, hochmoderne Produktentwicklung und potenzielle Diversifizierung in benachbarte Technologiebereiche umfasst. Dieser strategische Entwurf unterstreicht nicht nur Myomos Engagement für die Weiterentwicklung orthetischer Lösungen, sondern zeigt auch ihre Vision, Mobilitätsunterstützung für Menschen mit neurologischen Problemen neu zu definieren.

Myomo, Inc. (MYO) – Ansoff-Matrix: Marktdurchdringung

Steigern Sie die Direktvertriebsbemühungen an bestehende orthopädische Rehabilitationszentren und Krankenhäuser

Myomo, Inc. meldete im Jahr 2022 einen Gesamtumsatz von 4,8 Millionen US-Dollar, wovon 67 % aus Direktverkäufen an Rehabilitationszentren stammten. Das Unternehmen hat Partnerschaften mit 124 Gesundheitseinrichtungen in 38 Bundesstaaten aufgebaut.

Verkaufsmetrik	Leistung 2022
Insgesamt betreute Gesundheitseinrichtungen	124
Abgedeckte Staaten	38
Direkter Umsatz	3,22 Millionen US-Dollar

Erweitern Sie Marketingkampagnen, die sich an Ärzte und Physiotherapeuten richten

Die Marketingausgaben für 2022 beliefen sich auf 1,1 Millionen US-Dollar, wobei 42 % für gezielte Outreach-Programme für Ärzte und Therapeuten aufgewendet wurden.

• Sponsoring medizinischer Konferenzen: 18 Veranstaltungen
• Direkte Arztkommunikationskampagnen: 3.752 Einzelkontakte
• Investitionen in das Programm zur medizinischen Fortbildung (CME): 247.000 US-Dollar

Implementieren Sie gezielte digitale Marketingstrategien

Budget für digitales Marketing: 412.000 US-Dollar im Jahr 2022, wobei 53 % auf die Sensibilisierung für neurologische Rehabilitationstechnologien konzentriert sind.

Digitaler Marketingkanal	Engagement-Kennzahlen
LinkedIn-Kampagnen	87.500 professionelle Aufrufe
Medizinische Webinare	1.243 angemeldete Teilnehmer
Gezielte Online-Anzeigen	352.000 Impressionen

Entwickeln Sie wettbewerbsfähige Preisstrategien

Durchschnittspreis für MyoPro-Geräte: 5.890 US-Dollar, mit einer Reduzierung der Stückkosten um 22 % im Vergleich zum Vorjahr.

• Erstattungssatz der Versicherung: 68 % der Gerätekosten
• Mengenrabattprogramm für Großeinkäufe implementiert
• Die Finanzierungsmöglichkeiten wurden auf 14 Zahlungsnetzwerke im Gesundheitswesen erweitert

Verbessern Sie Kundensupport und Schulungsprogramme

Investition in den Kundensupport: 673.000 US-Dollar im Jahr 2022, einschließlich Schulung und technischer Unterstützung.

Support-Metrik	Leistung 2022
Öffnungszeiten des technischen Supports	5.412 Gesamtstunden
Schulungssitzungen durchgeführt	87 umfassende Programme
Kundenzufriedenheitsrate	94.3%

Myomo, Inc. (MYO) – Ansoff-Matrix: Marktentwicklung

Erweitern Sie die geografische Reichweite auf internationale Märkte

Myomo, Inc. meldete für das vierte Quartal 2022 einen Umsatz von 5,8 Millionen US-Dollar, wobei die internationale Marktexpansion auf Europa und Asien ausgerichtet ist. Der weltweite Markt für Orthesen für die oberen Extremitäten soll bis 2027 ein Volumen von 1,2 Milliarden US-Dollar erreichen.

Marktregion	Potenzielle Marktgröße	Prognostiziertes Wachstum
Europa	380 Millionen Dollar	7,5 % CAGR
Asien-Pazifik	450 Millionen Dollar	9,2 % CAGR

Erschließen Sie neue Gesundheitssegmente

Das US-Gesundheitssystem für Veteranen versorgt jährlich etwa 9 Millionen Veteranen. Der Markt für militärische Rehabilitation wird im Jahr 2022 auf 2,3 Milliarden US-Dollar geschätzt.

• Potenzieller Markt für das Gesundheitssystem Veterans Affairs (VA).
• Abdeckung militärischer Rehabilitationszentren
• Segment der neurologischen Rehabilitation

Partnerschaften entwickeln

Myomo arbeitet derzeit mit 47 Rehabilitationskliniken in den Vereinigten Staaten zusammen. Angestrebte Erweiterung auf 75 Kliniken bis Ende 2023.

Partnerschaftstyp	Aktuelle Nummer	Zielnummer
Rehabilitationskliniken	47	75
Spezialisierte medizinische Netzwerke	12	25

Chancen in Schwellenländern

Der weltweite Markt für neurologische Rehabilitation wird bis 2026 voraussichtlich 17,5 Milliarden US-Dollar erreichen, mit einer durchschnittlichen jährlichen Wachstumsrate von 6,8 %.

Engagement des Versicherungsanbieters

Aktueller Versicherungsschutz für MyoPro-Geräte bei 62 %. Ziel ist es, die Abdeckung bis 2024 auf 85 % zu erhöhen.

Metrik für den Versicherungsschutz	Aktueller Prozentsatz	Zielprozentsatz
Geräteabdeckung	62%	85%

Myomo, Inc. (MYO) – Ansoff-Matrix: Produktentwicklung

Verbessern Sie die bestehende MyoPro-Orthesentechnologie

Myomo, Inc. investierte im Jahr 2022 2,3 Millionen US-Dollar in Forschung und Entwicklung für Sensortechnologie. Die Entwicklung KI-gesteuerter Fähigkeiten kostete im Geschäftsjahr etwa 1,7 Millionen US-Dollar.

Technologieinvestitionen	Betrag ($)
Forschung und Entwicklung im Bereich Sensorik	2,300,000
Entwicklung von KI-Fähigkeiten	1,700,000

Entwickeln Sie leichtere und ergonomischere Design-Iterationen

Aktuelles Gewicht des MyoPro-Geräts: 2,2 Pfund. Angestrebte Gewichtsreduzierung: 0,5 Pfund in der nächsten Design-Iteration.

• Materialforschungsbudget: 750.000 US-Dollar
• Kosten für die Prototypenentwicklung: 450.000 US-Dollar
• Entwurfsiterationszyklus: 18 Monate

Erstellen Sie spezielle Produktvarianten

Marktpotenzial für neurologische krankheitsspezifische Geräte: 42,6 Millionen US-Dollar bis 2025.

Neurologischer Zustand	Geschätzte Marktgröße
Erholung nach einem Schlaganfall	18,500,000
Multiple Sklerose	12,300,000
Zerebralparese	11,800,000

Verbessern Sie die Akkulaufzeit und die drahtlose Konnektivität

Aktuelle Akkulaufzeit: 4 Stunden. Zielverbesserung: 6 Stunden bis 2024.

• Investition in Batterietechnologie: 1,1 Millionen US-Dollar
• Forschung und Entwicklung für drahtlose Konnektivität: 900.000 US-Dollar
• Erwartete Verbesserung der Konnektivitätsreichweite: 50 %

Personalisierte Kalibriertechnologien

Entwicklungsbudget für benutzerspezifische Anpassungstechnologie: 1,5 Millionen US-Dollar im Jahr 2023.

Kalibrierungsfunktion	Entwicklungskosten ($)
Algorithmen für maschinelles Lernen	650,000
Adaptive Sensorkalibrierung	450,000
Anpassung der Benutzeroberfläche	400,000

Myomo, Inc. (MYO) – Ansoff-Matrix: Diversifikation

Entdecken Sie benachbarte Märkte für Medizintechnik

Größe des globalen Marktes für Prothetik: 6,3 Milliarden US-Dollar im Jahr 2022, voraussichtlich 9,5 Milliarden US-Dollar bis 2030.

Marktsegment	Aktueller Marktwert	Wachstumspotenzial
Roboter-Rehabilitationsausrüstung	2,1 Milliarden US-Dollar	12,4 % CAGR
Assistive Mobilitätstechnologien	3,8 Milliarden US-Dollar	14,2 % CAGR

Entwickeln Sie komplementäre Softwareplattformen

Markt für digitale Gesundheitsüberwachungssoftware: 245,1 Milliarden US-Dollar bis 2025.

• Entwicklungskosten für Software zur Patientenverfolgung: 500.000 bis 1,2 Millionen US-Dollar
• Durchschnittliche Implementierungszeit: 8-12 Monate
• Mögliche Marktdurchdringung: 35 % der Rehabilitationszentren

Untersuchen Sie sportmedizinische Anwendungen

Markt für Sportmedizintechnologie: 7,2 Milliarden US-Dollar im Jahr 2022.

Anwendungsbereich	Marktgröße	Wachstumsrate
Sportliche Leistungsrehabilitation	1,6 Milliarden US-Dollar	9,7 % CAGR
Tragbare Rehabilitationstechnologien	890 Millionen Dollar	15,3 % CAGR

Strategische Akquisitionsstrategie

Kosten für die Akquisition eines Medizintechnik-Startups: 5 bis 50 Millionen US-Dollar.

• Durchschnittliche Startwertbewertung im Bereich unterstützender Technologien: 12,3 Millionen US-Dollar
• Mögliche Akquisitionsziele: 7-12 Unternehmen
• Erforderliche Investition: 15–30 Millionen US-Dollar

Erweitern Sie die Forschung zu unterstützenden Technologien

Markt für mobilitätseingeschränkte Assistenztechnologien: 26,8 Milliarden US-Dollar bis 2027.

Forschungsschwerpunkt	Geschätzte Investition	Mögliche Auswirkungen
Fortschrittliche Mobilitätslösungen	3,5 Millionen Dollar	Erreichen Sie 40 % mehr Patienten
Neuronale Schnittstellentechnologien	4,2 Millionen US-Dollar	Verbessern Sie die Rehabilitationsergebnisse

Myomo, Inc. (MYO) - Ansoff Matrix: Market Penetration

You're looking at how Myomo, Inc. (MYO) is driving growth by selling more of its existing MyoPro device into its current US market, which is the essence of Market Penetration. This strategy relies heavily on deepening relationships with existing customer channels and improving the efficiency of patient acquisition.

The company's financial trajectory in 2025 shows a push for volume, even as revenue growth moderated from the initial post-Medicare Part B surge. Full-year 2025 revenue guidance was updated to a range of $40 million to $42 million, representing growth of 23% to 29% over 2024. Quarterly revenue performance saw $9.8 million in Q1, followed by $9.7 million in Q2, and then a slight rebound to $10.1 million in Q3. To be fair, the initial high growth rates are harder to sustain, but the underlying unit volume is still increasing; Q1 saw 182 units delivered (up 100% YoY), and Q3 saw 186 units delivered (up 16% YoY). This focus on volume is key to leveraging the fixed cost base, as evidenced by the gross margin remaining strong, at 67.2% in Q1 2025.

Here's a quick look at how the key financial and operational metrics stacked up through the first three quarters of 2025:

Metric	Q1 2025 Data	Q3 2025 Data	Context/Change
Revenue	$9.8 million	$10.1 million	Q3 revenue up 10% YoY
MyoPro Units Delivered	182	186	Q1 units up 100% YoY
Gross Margin	67.2%	63.8% (Quarter)	Q1 margin up 600 bps from Q1 2024
Patient Pipeline End of Period	1,482	1,669	Pipeline up 32% YoY as of Q3
Cost per Pipeline Add	~$2,300 (early Q1 estimate)	$2,589	Q3 cost down 5% sequentially
O&P Channel Revenue	$475,000	$900,000	Q3 O&P revenue up 154% YoY

Increase direct sales force coverage in top 100 US rehabilitation hospitals.

While specific numbers on the direct sales force coverage within the top 100 US rehabilitation hospitals aren't explicitly broken out, the growth in institutional penetration is clear through the Orthotics and Prosthetics (O&P) channel. This channel is a key focus for market penetration, as it offers a lower-cost source of qualified patients. O&P channel revenue hit a quarterly record of $900,000 in Q3 2025, marking a 154% year-over-year increase. Furthermore, more than 100 VA medical centers have placed orders for the MyoPro, showing success in penetrating large federal healthcare systems. The company ended Q1 2025 with more than 300 CPOs trained, a significant increase from the 160 trained at the start of the year, indicating a rapid expansion of the clinical footprint capable of dispensing the device.

Secure favorable coverage policies from major national private payers.

Deepening payer coverage directly translates to market penetration by removing the financial barrier for patients. Myomo, Inc. has been actively contracting, with signed or pending contracts with a number of state Blue Cross Blue Shield (BCBS) plans covering 18.6 million lives as of early 2025. Overall, the company reports having entered into contracts with commercial payers covering over 25 million lives. These efforts build upon the foundation set by Medicare Part B coverage, which began in April 2024 and accounted for 60% of Q1 2025 revenue.

Launch patient-direct digital marketing to reduce referral friction.

Direct-to-patient marketing remains a primary driver, though efficiency has been a focus. Early in Q1 2025, lead generation was disrupted by changes to Meta advertising policies, which increased the cost per pipeline add to approximately $2,300. However, management noted adjustments led to a rebound, achieving record lead generation in April. The company is shifting its advertising mix; for instance, the cost per direct billing pipeline add in Q2 2025 was $2,926, but by Q3, the cost per pipeline add fell to $2,589, a 5% sequential decline, suggesting marketing adjustments are taking hold. Social media is cited as the most efficient medium, though TV ads are used to educate the audience and lift digital results.

Streamline the insurance pre-authorization process for faster patient onboarding.

Friction in the authorization process slows down revenue conversion. In Q1 2025, the company ended the quarter with a backlog of 249 patients, a 9% decrease year-over-year, suggesting faster conversion velocity. This velocity improved in Q3 2025, where 57% of revenue units came from intra-quarter fill units, up from 24% a year ago. Management continues to engage with payer medical directors to address high denial rates, particularly from Medicare Advantage plans, which forces the company into an appeals process that can delay service.

Expand clinical training for occupational therapists to drive MyoPro utilization.

Scaling utilization requires a trained clinical base. Beyond the O&P channel growth, the company is investing in its clinical network. As noted, more than 300 CPOs completed initial training by the end of Q1 2025. The company also launched the Myomo Academy to provide ongoing, structured education for clinicians. This training effort supports the new MyoConnect program, which aims to engage therapists and physicians nationwide to generate recurring patient referrals, viewing this as a more scalable way to grow the pipeline while lowering the cost per pipeline add.

Finance: draft 13-week cash view by Friday.

Myomo, Inc. (MYO) - Ansoff Matrix: Market Development

You're looking at expanding Myomo, Inc. (MYO) into new geographic territories, which is exactly what Market Development is all about. We need to map out where the existing MyoPro device can find new customers, focusing on regions where the path to purchase-reimbursement-is clearest.

Prioritizing regulatory clearance, like the CE Mark for Western Europe, is a necessary first step to unlock those markets. While we don't have a specific CE Mark date as of late 2025, we see momentum in existing European distribution. For instance, in the first quarter of 2025, international revenue, which is primarily driven by Germany, hit $1.3 million, marking a 42% year-over-year increase. This growth shows that the regulatory hurdle, once cleared, translates quickly into sales velocity in established markets.

Regarding Japan, the latest public strategy points to a licensing approach. Back in 2019, Myomo, Inc. announced a business development program targeting Japan, Korea, China, India, and the Middle East through technical licensing arrangements with local partners capable of manufacturing and distribution. You'll want to check the latest investor decks to see if this specific market has moved from the planning stage to active distribution, as recent quarterly reports don't detail a specific 2025 partnership there.

For large-scale procurement, the centrally-funded national healthcare systems are the biggest prize. In the U.S. context, Medicare Part B is our concrete example of this. You should note that Medicare Part B patients accounted for 54% of Myomo, Inc.'s third quarter 2025 revenue. Targeting similar national or large regional systems abroad is key to securing volume orders, not just individual sales.

Focusing initial international efforts on countries with established orthotics reimbursement is defintely the smart play for near-term return. Myomo, Inc.'s international distributors in six countries-Germany, Denmark, the U.K., Italy, Chile, and Australia-are already adopting the U.S. screening day marketing model. These efforts have already resulted in successful reimbursement achievements in several of those countries.

To assess market viability in Canada, pilot programs are essential to understand local reimbursement pathways, even if we haven't seen recent public updates on specific Myomo, Inc. trials there. The complexity of the patient journey, which can take months or years to convert awareness into an order, means any new market needs a dedicated, measured entry strategy.

Here's a quick look at the recent financial and unit performance that underpins this international push:

Metric	Value (2025)	Period/Context
Full Year Revenue Guidance	$40 million to $42 million	Fiscal Year 2025
Year-to-Date Revenue	$29.6 million	Nine Months Ended September 30, 2025
Q3 Revenue Units	186	Q3 2025
Average Selling Price (ASP)	Approximately $54,200	Q3 2025
Medicare Part B Revenue Share	54%	Q3 2025
International Revenue	$1.3 million	Q1 2025 (Primarily Germany)

The expansion strategy relies on building out the clinical network, which is a key operational component of Market Development. By the end of the first quarter of 2025, Myomo, Inc. had more than 300 Certified Prosthetists Orthotists (CPOs) complete initial MyoPro training. This growing base of trained clinicians across international markets is what supports the sales effort.

You'll want to track the progress of the MyoConnect program, which is designed to strengthen relationships with therapists and physicians to generate recurring patient referrals, as this directly impacts the pipeline quality needed for international scale.

Myomo, Inc. (MYO) - Ansoff Matrix: Product Development

Myomo, Inc. has been actively advancing its core offering, having already introduced two product upgrades in early 2025: the MARK 2 clinical unit and the MyoPro 2x. This continuous innovation is supported by the investment made into engineering capabilities. For instance, operating expenses in the first quarter of 2025 reached $10.1 million, which included increased research and development expenditures, up from $3.8 million in revenue for that same period.

The focus on engineering new models and designs directly relates to improving the unit economics of the flagship device. You see the current Average Selling Price (ASP) hovering around $54,200 as of the third quarter of 2025, following an ASP of approximately $54,200 in Q2 2025 and $54,000 in Q1 2025. The company is actively working on manufacturing cost reduction projects that are expected to generate an aggregate gross margin improvement of 200 basis points, with savings fully realized starting in the third quarter of 2026. This aligns with the goal of engineering a modular design to simplify repairs and reduce long-term service costs.

The investment in product development is set against a backdrop of scaling the business. For the nine months ended September 30, 2025, year-to-date operating expenses were $30.7 million. The company is projecting full-year 2025 revenue between $40 million to $42 million. The pipeline of potential patients is growing, standing at 1,669 patients in process as of September 30, 2025.

Here's a quick look at the recent product delivery and pipeline metrics:

Metric	Q1 2025	Q2 2025	Q3 2025
Revenue Units Delivered	182	178	186
Average Selling Price (ASP)	$54,000	$54,200	$54,200
New Pipeline Adds	700	816	826
Cost Per Pipeline Add	$2,300	$2,926	$2,589

The strategic product development roadmap includes several key initiatives aimed at market expansion and cost management:

• Develop a smaller, lighter device model specifically for the pediatric patient population.
• Introduce a software-as-a-service upgrade for enhanced functionality and data collection.
• Create a lower-cost, non-powered orthotic device as an entry point for new patients.
• Integrate the device with telehealth platforms for remote adjustments and patient monitoring.
• Engineer a modular device design to simplify repairs and reduce long-term service costs.

To support the pipeline growth, the company is also focusing on channel efficiency; for example, the cost per pipeline add in Q3 2025 was $2,589, a sequential decline of 5% due to marketing changes, including the MyoConnect program. Still, operating expenses in Q2 2025 were $10.6 million, with advertising costs reaching $2.2 million in that quarter. The company has taken steps to manage costs, including a July headcount reduction of about 8% of the U.S. workforce, expected to save at least $2 million in operating expenses and capital expenditures over the next 12 months.

Finance: draft 13-week cash view by Friday.

Myomo, Inc. (MYO) - Ansoff Matrix: Diversification

You're looking at how Myomo, Inc. (MYO) can move beyond its core upper-limb orthotic business, which, to be fair, is showing growth-Year-to-date revenue through September 30, 2025, hit $29.6 million, up from $20.48 million the prior year for the same period, but the net loss also widened to $11.8 million year-to-date. Diversification here means taking that core myoelectric sensing and control expertise into entirely new product or market spaces. It's aggressive, but the potential market sizes suggest why the move is worth analyzing.

Here's a quick look at the financial baseline you're starting from as of the end of Q3 2025:

Metric	Value (as of Sep 30, 2025)	Context
FY 2025 Revenue Guidance	$40 million to $42 million	Represents over 23% growth versus 2024
Q3 2025 Revenue	$10.1 million	Up 10% year-over-year
Q3 2025 Net Loss	$3.7 million	Compared to a net loss of $1.0 million in Q3 2024
Cash & Equivalents	$12.6 million	Sufficient to fund operations for at least the next 12 months
Q3 2025 Gross Margin	63.8%	Down from 75.4% in Q3 2024
Debt-to-Equity Ratio	0.71	Indicates moderate leverage

The diversification paths below aim to either apply the existing technology to new customer bases or develop entirely new technology platforms that leverage the company's expertise in human-machine interface.

Develop a non-orthotic wearable sensor system for general rehabilitation data analytics.

This strategy moves Myomo, Inc. (MYO) from selling a specific medical device to selling data insights-a shift to a software/service revenue stream. The market for this is substantial, moving beyond just upper-limb paralysis to the broader rehabilitation space. The Healthcare Big Data Analytics Market was valued at $46.80 Billion in 2024 and is projected to hit $123.51 Billion by 2033, growing at a CAGR of 11.28% from 2025-2033. If you look at the general Data Analytics Market, it was estimated at $82.23 billion in 2025. The key here is monetizing the sensor data Myomo already collects, perhaps by offering analytics subscriptions to physical therapy clinics or insurance payers for remote patient monitoring.

Enter the industrial exoskeleton market for worker safety and heavy lifting assistance.

This is a market expansion into the industrial sector, using the core actuation and control knowledge, but for different use cases like ergonomics and safety. The Industrial Exoskeleton Market is estimated to be valued at $0.57 billion in 2025, with projections to reach $1.48 billion by 2030, showing a CAGR of 21.19%. Another projection puts the market at $1.4 billion in 2025, growing at a 30.0% CAGR to 2035. This segment is seeing adoption in logistics and construction, where passive exoskeletons have been shown to cut back-extensor activity by 35% during carton handling. You'd be competing against established players, but the growth rate is attractive.

License the core myoelectric control technology to other medical device companies.

Licensing is a capital-light way to generate revenue from intellectual property (IP) without the manufacturing and sales overhead Myomo, Inc. (MYO) currently manages. The broader Technology Licensing Market was valued at $1.29 Billion in 2023 and is projected to reach $2.20 Billion by 2031, growing at a CAGR of 11.22%. For context, the entire Medical Device Technology Market is estimated at $575.6 billion in 2025. A successful license agreement could provide immediate, high-margin, non-dilutive cash flow, which is critical given the year-to-date net loss of $11.8 million as of Q3 2025.

Acquire a small company specializing in lower-limb mobility devices to expand the product line.

This is a product line extension through acquisition, moving into the lower-limb space where Myomo, Inc. (MYO) has no current presence. The Powered Prosthetics Market size is estimated at $1.9 Bn in 2025, with lower extremity prosthetics accounting for approximately 45% of that share. The overall market is projected to grow at a CAGR of 8.6% through 2032. An acquisition would immediately diversify revenue away from upper-limb focus and potentially leverage existing insurance billing infrastructure, though integration risk is high.

Create a virtual reality rehabilitation platform using MyoPro data for home therapy.

This is a product development play that integrates the existing device data into a new software product for the home setting. The Virtual Rehabilitation Market size is estimated at $0.82 billion in 2025, with a strong CAGR of 24.1% projected from 2024. The specific application segment of rehabilitation and physical therapy within the broader VR in Healthcare Market is forecast to expand at a 29.40% CAGR to 2030. This move aligns with the trend toward decentralized, data-rich healthcare ecosystems, potentially improving patient adherence and providing richer data streams for the analytics platform mentioned above.

The potential market sizes for these diversification avenues are significant, with several segments showing CAGRs well above 20%, which contrasts with Myomo, Inc. (MYO)'s current revenue growth guidance of over 23% for 2025.

• Rehabilitation Data Analytics (Healthcare Segment CAGR): 11.28%
• Industrial Exoskeleton Market (2025-2030 CAGR): 21.19%
• Technology Licensing Market (2024-2031 CAGR): 11.22%
• Powered Prosthetics Market (2025-2032 CAGR): 8.6%
• Virtual Rehabilitation Market (2024-2025 CAGR): 24.1%